“Through CRISPR RNA optimization, we achieved around 59% editing at the TTR locus in our in vitro experiments. In the mouse ...
Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...
CRISPR has the power to correct genetic mutations, but current delivery methods are either unsafe or inefficient, keeping the technology from reaching its full medical potential. With the power to ...
A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...
Clinical Trials Arena on MSN
JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death
Intellia Therapeutics CEO John Leonard explained the circumstances of the patient death at the JP Morgan Healthcare ...
Despite pipeline setbacks and slow CASGEVY rollout, future revenue acceleration and expansion into cardiovascular and autoimmune diseases offer significant long-term growth opportunities. CRISPR ...
CRISPR Therapeutics (CRSP) earns a Hold rating as pipeline breadth grows but CASGEVY's launch remains slow and economically unattractive. CRSP’s in vivo editing platform shows strong early validation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results